ASP-4345

ASP-4345
Clinical data
Other namesASP4345
Routes of
administration		Oral[1][2][3]
Drug classDopamine D1 receptor positive allosteric modulator
ATC code
  • None
Pharmacokinetic data
Elimination half-life9.1–26.8 hours[3]
Identifiers
  • 2-(5-chloro-2-oxo-1,3-benzoxazol-3-yl)-N-methyl-N-[[6-(trifluoromethyl)-1H-benzimidazol-2-yl]methyl]acetamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC19H14ClF3N4O3
Molar mass438.79 g·mol−1
3D model (JSmol)
  • CN(CC1=NC2=C(N1)C=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(C=CC(=C4)Cl)OC3=O
  • InChI=1S/C19H14ClF3N4O3/c1-26(8-16-24-12-4-2-10(19(21,22)23)6-13(12)25-16)17(28)9-27-14-7-11(20)3-5-15(14)30-18(27)29/h2-7H,8-9H2,1H3,(H,24,25)
  • Key:YJODOMNPYLHYJK-UHFFFAOYSA-N

ASP-4345, or ASP4345, is a dopamine D1 receptor positive allosteric modulator which is or was under development for the treatment of schizophrenia.[1][4][5][3] It is being developed as an adjunctive therapy for the cognitive symptoms of schizophrenia.[1] The drug is taken orally.[1][2][3]

The most common side effects of ASP-4345 have been found to be headache and somnolence.[2] No changes in mood or suicidality were observed.[2] The pharmacokinetics of ASP-4345 have been studied.[3] The median time to peak levels of ASP-4345 is 1.0 to 3.0 hours.[3] Its mean elimination half-life is 9.1 to 26.8 hours.[3]

ASP-4345 is or was under development by Astellas Pharma.[1][4] As of March 2021, no recent development has been reported.[1] The drug has reached phase 2 clinical trials for schizophrenia.[1][4] It was found to be ineffective in a phase 2 trial.[5]

See also

References

  1. ^ a b c d e f g "ASP 4345". AdisInsight. 9 March 2021. Retrieved 27 May 2026.
  2. ^ a b c d Desai A, Benner L, Wu R, Gertsik L, Maruff P, Light GA, et al. (May 2021). "Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia". Neuropsychopharmacology. 46 (6): 1145–1151. doi:10.1038/s41386-020-00908-0. PMC 8182805. PMID 33203954.
  3. ^ a b c d e f g Desai A, Benner L, Wu R, Gertsik L, Uz T, Marek GJ, et al. (January 2021). "Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies". Clinical Pharmacokinetics. 60 (1): 79–88. doi:10.1007/s40262-020-00911-0. PMC 7808976. PMID 32533536.
  4. ^ a b c "Delving into the Latest Updates on ASP-4345 with Synapse". Synapse. 15 November 2025. Retrieved 27 May 2026.
  5. ^ a b Martínez AL, Brea J, Rico S, de Los Frailes MT, Loza MI (September 2021). "Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments". International Journal of Molecular Sciences. 22 (18): 9905. doi:10.3390/ijms22189905. PMC 8468549. PMID 34576069.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.